MichaelLanutiMD
Thoracic Surgery • Boston, MAAdult General Thoracic Surgery, Thoracic Surgical Oncology
Associate Professor of Surgery, Harvard Medical School
Dr. Lanuti is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
55 Fruit St
Blk 1570 Thoracic Surgery Department
Boston, MA 02114Phone+1 617-726-6751Fax+1 617-726-7667
Summary
- Dr. Michael Lanuti is a thoracic surgeon in Boston, MA and is affiliated with Massachusetts General Hospital. He received his medical degree from Perelman School of Medicine at the University of Pennsylvania and has been in practice 23 years. He specializes in thoracic surgical oncology and is experienced in adult general thoracic surgery and thoracic surgical oncology.He is the director of Thoracic Oncology for the Division of Thoracic Surgery.
Education & Training
Massachusetts General HospitalFellowship, Thoracic Surgery, 2001 - 2004
University of Pennsylvania Health SystemResidency, Surgery, 1994 - 2001
Perelman School of Medicine at the University of PennsylvaniaClass of 1994
Certifications & Licensure
MA State Medical License 2001 - 2026
ME State Medical License 2020 - 2026
NH State Medical License 2021 - 2025
PA State Medical License 1995 - 2024
RI State Medical License 2021 - 2022- American Board of Surgery Surgery
- American Board of Thoracic Surgery Thoracic and Cardiac Surgery
Awards, Honors, & Recognition
- Fellow (FACS) American College of Surgeons
Clinical Trials
- Neoadjuvant Chemotherapy or Chemoradiotherapy in Resectable Oesophageal Carcinoma（NewEC Study） Start of enrollment: 2018 Nov 14
- Evaluation of PET Probe [68Ga]CBP8 in the Detection of Radiation Induced Tissue Injury Start of enrollment: 2020 Jul 19
Publications & Presentations
PubMed
- 38 citationsPrecise reconstruction of the TME using bulk RNA-seq and a machine learning algorithm trained on artificial transcriptomes.Aleksandr Zaitsev, Maksim Chelushkin, Daniiar Dyikanov, Ilya Cheremushkin, Boris Shpak
Cancer Cell. 2022-08-08 - 127 citationsMouse model of carbon tetrachloride induced liver fibrosis: Histopathological changes and expression of CD133 and epidermal growth factorTsutomu Fujii, Bryan C. Fuchs, Suguru Yamada, Gregory Y. Lauwers, Yakup Kulu
BMC Gastroenterology. 2010-07-09 - 617 citationsNon-Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology.David S Ettinger, Douglas E Wood, Dara L Aisner, Wallace Akerley, Jessica R Bauman
Journal of the National Comprehensive Cancer Network. 2022-05-01
Journal Articles
- Programmed Death Ligand 1 and CD8+ Immune Cell Infiltrates in Resected Primary Tracheal Malignant NeoplasmsMichael Lanuti, Harald C Ott, Douglas J Mathisen, Angela Shih, Ashok Muniappan, Henning A Gaissert, European Journal of Cardio-Thoracic Surgery
- Pioglitazone Reduces Hepatocellular Carcinoma Development in Two Rodent Models of CirrhosisKenneth K Tanabe, Ricard Masia, Derek J Erstad, Michael Lanuti, Journal of gastrointestinal surgery
Press Mentions
OncLive® Presents State of the Science Summit™ on Non-Small Cell Lung CancerJune 10th, 2019
DiscussionDecember 12th, 2017
Collagen-Targeting PET Probe May Improve Diagnosis and Treatment of Pulmonary FibrosisApril 5th, 2017- Join now to see all
Professional Memberships
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
